Predictors of hematoma expansion in acute intracerebral hemorrhage

描述（由申请人提供）：项目概述：Goldstein博士是一名急诊医生，其长期目标是改善神经系统急诊患者的护理。脑出血（ICH）是最致命的中风形式，目前尚无有效的治疗方法。血肿扩大是这种疾病最可怕的并发症，针对这种扩大的治疗可能是改善预后的关键。扩展的床边预测器将允许急性治疗专门针对那些可能受益的患者，同时使那些不会发展扩展的患者免受此类治疗的副作用。Goldstein博士在基础和临床研究方面有着坚实的基础，并在两位国家认可的ICH和急诊医学专家的指导下寻求研究方法和教师发展方面的进一步培训。格林伯格博士和卡马戈博士有独立的校外资助记录，并指导临床医生谁已发展成为积极的临床研究者。该建议包括神经病学，神经放射学，急诊医学和生物统计学的临床专家的紧密结合。这项对急性脑出血患者的前瞻性观察性研究有以下目的：1）确定CT血管造影（CTA）显示的造影剂外渗是否预测随后的血肿扩大; 2）确定造影剂外渗是否独立预测不良的长期结局; 3）确定急性环境中的血清生物标志物是否预测血肿扩大; 4）开发可用于急性指导治疗的预测规则; 5）获得神经放射学和使用成像对患者进行紧急风险分层的正式培训; 6）通过哈佛公共卫生学院的硕士课程获得生物统计学和流行病学的正式培训。该提案将为未来的试验奠定基础，指导对有血肿扩大风险的患者进行急性治疗。该培训补助金将为Goldstein博士转变为一名独立的临床科学家提供关键支持，该科学家在神经系统紧急情况下进行以患者为导向的研究。相关性：中风最致命的形式是脑出血。虽然一些治疗方法可能会有所帮助，但它们也有副作用，我们不知道哪些人会从这些治疗中获得更多的好处而不是伤害。这项提案将建立一种使用CT扫描和血液测试来决定谁将从哪种治疗中受益的方法。

DESCRIPTION (provided by applicant): PROJECT SUMMARY: Dr. Goldstein is an emergency physician with a long-term goal of improving the care of patients with neurological emergencies. Intracerebral hemorrhage (ICH) is the most fatal form of stroke, and no proven therapies are available. Hematoma expansion is the most feared complication of this disease, and therapies targeting this expansion are likely to be critical for improving outcome. A bedside predictor of expansion would allow acute therapies to be specifically targeted to those patients likely to benefit, while sparing those who will not develop expansion from the side effects of such therapies. Dr. Goldstein has an established foundation in basic and clinical research, and seeks further training in research methods and faculty development under the mentorship of two nationally recognized experts in ICH and emergency medicine. Drs. Greenberg and Camargo have a track record of independent extramural funding, and of mentoring clinicians who have developed into active clinical investigators. This proposal includes the close integration of clinical specialists in neurology, neuroradiology, emergency medicine, and biostatistics. This prospective observational study of patients with acute intracerebral hemorrhage has the following aims: 1) Determine whether contrast extravasation visualized on CT angiography (CTA) predicts subsequent hematoma expansion; 2) Determine whether contrast extravasation independently predicts poor long-term outcome; 3) Determine whether serum biomarkers in the acute setting predict hematoma expansion; 4) Develop a prediction rule that can be used to acutely guide therapy; 5) Obtain formal training in neuroradiology and the use of imaging to emergently risk-stratify patients; 6) Obtain formal training in biostatistics and epidemiology through a Master's level program at the Harvard School of Public Health. The proposal will lay the foundations for future trials guiding acute therapy to patients at risk of hematoma expansion. This training grant will provide critical support for Dr. Goldstein's transition into an independent clinical scientist who performs patient-oriented research in neurologic emergencies. RELEVANCE: The most deadly form of stroke is bleeding in the brain. While some treatments may help, they also have side effects, and we don't know which people will receive more benefit than harm from these therapies. This proposal will establish a way to use CT scans and blood tests to decide who will benefit from which treatment.